Overview
- In ASCENT-03 for immunotherapy‑ineligible advanced triple‑negative breast cancer, sacituzumab govitecan improved progression‑free survival to 9.7 months vs 6.9 with chemotherapy (HR 0.62; P < .001).
- Patient‑reported outcomes from ASCENT-03 showed maintained physical functioning and broader quality‑of‑life advantages with sacituzumab govitecan despite more gastrointestinal symptoms.
- In ASCENT-07 for HR‑positive/HER2‑negative disease after endocrine therapy and before chemotherapy, the primary endpoint was not met, with median PFS 8.3 months in both arms by blinded independent review (HR 0.85; P = .130).
- Overall survival findings remain immature with limited follow‑up and heavy crossover in control arms, including 61% receiving sacituzumab after progression in ASCENT-07, with investigators reporting an early trend favoring the drug.
- Across studies, higher rates of grade ≥3 adverse events—especially neutropenia and leukopenia—were observed with sacituzumab govitecan compared with chemotherapy.